Log In
BCIQ
Print this Print this
 

glesatinib (MGCD265)

  Manage Alerts
Collapse Summary General Information
Company Mirati Therapeutics Inc.
DescriptionSmall molecule dual inhibitor of c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene) and AXL receptor tyrosine kinase (AXL; UFO)
Molecular Target c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene) ; AXL receptor tyrosine kinase (AXL) (UFO)
Mechanism of Actionc-Met receptor tyrosine kinase inhibitor; AXL receptor tyrosine kinase (AXL) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/21/2015

Undisclosed

Undisclosed

Undisclosed

12/21/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today